Clinical review of a long-acting, injectable formulation of risperidone

Knox, Erin D.; Stimmel, Glen L.

doi:10.1016/j.clinthera.2004.12.009

Cited by 71 publications

(41 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A slow crossover titration is preferred and close monitoring of mental state, side effects and rebound phenomena is essential during switching (Knox and Stimmel, 2004). Potential adverse events during crossover include the following:…”

Section: Switching Medicationsmentioning

confidence: 99%

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders

Galletly

Castle

Dark

et al. 2016

Aust N Z J Psychiatry

641

672

View full text Add to dashboard Cite

Objectives: This guideline provides recommendations for the clinical management of schizophrenia and related disorders for health professionals working in Australia and New Zealand. It aims to encourage all clinicians to adopt best practice principles. The recommendations represent the consensus of a group of Australian and New Zealand experts in the management of schizophrenia and related disorders. This guideline includes the management of ultra-high risk syndromes, first-episode psychoses and prolonged psychoses, including psychoses associated with substance use. It takes a holistic approach, addressing all aspects of the care of people with schizophrenia and related disorders, not only correct diagnosis and symptom relief but also optimal recovery of social function. Methods:The writing group planned the scope and individual members drafted sections according to their area of interest and expertise, with reference to existing systematic reviews and informal literature reviews undertaken for this guideline. In addition, experts in specific areas contributed to the relevant sections. All members of the writing group reviewed the entire document. The writing group also considered relevant international clinical practice guidelines. Evidence-based recommendations were formulated when the writing group judged that there was sufficient evidence on a topic. Where evidence was weak or lacking, consensus-based recommendations were formulated. Consensus-based recommendations are based on the consensus of a group of experts in the field and are informed by their agreement as a group, according to their collective clinical and research knowledge and experience. Key considerations were selected and reviewed by the writing group. To encourage wide community participation, the Royal Australian and New Zealand College of Psychiatrists invited review by its committees and members, an expert advisory committee and key stakeholders including professional bodies and special interest groups. RANZCP GuidelinesGalletly et al. 411 Australian & New Zealand Journal of Psychiatry, 50(5)Results: The clinical practice guideline for the management of schizophrenia and related disorders reflects an increasing emphasis on early intervention, physical health, psychosocial treatments, cultural considerations and improving vocational outcomes. The guideline uses a clinical staging model as a framework for recommendations regarding assessment, treatment and ongoing care. This guideline also refers its readers to selected published guidelines or statements directly relevant to Australian and New Zealand practice. Conclusions:This clinical practice guideline for the management of schizophrenia and related disorders aims to improve care for people with these disorders living in Australia and New Zealand. It advocates a respectful, collaborative approach; optimal evidence-based treatment; and consideration of the specific needs of those in adverse circumstances or facing additional challenges.

show abstract

Section: Switching Medicationsmentioning

confidence: 99%

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders

Galletly

Castle

Dark

et al. 2016

Aust N Z J Psychiatry

641

672

View full text Add to dashboard Cite

show abstract

“…(18). According to some authors, rapid dose increase of antipsychotics may also be a factor in inducing peripheral edema.…”

Section: Discussionmentioning

confidence: 99%

Rapid Onset of Pedal Edema Associated with Risperidone in Two Male Patients: Simultaneous Clinical Cases

Örüm¹,

Almış²,

Karaca³

2017

JMOOD

View full text Add to dashboard Cite

“…Depot formulations augment the impact of oral formulations by providing further reductions in morbidity and mortality (Kane et al 2003). Because they bypass the gastrointestinal tract, depot treatments decrease the amount of medication needed and may minimize certain peripheral side effects including hepatotoxicity and hyperprolactinemia (Knox and Stimmel 2004). However, depot formulations have limitations that restrict more significant improvements in adherence and efficacy (Kane et al 1998).…”

Section: Introductionmentioning

confidence: 99%

In vitro and in vivo demonstration of risperidone implants in mice

Rabin

Liang

Ehrlichman

et al. 2008

Schizophrenia Research

View full text Add to dashboard Cite

Background-Nonadherence with medication is a critical limitation in current long-term treatment of schizophrenia and a primary factor in poor quality-of-life outcomes. However, few treatments have addressed this shortcoming using an implantable drug delivery approach. The goal of this study was to provide in vitro and in vivo proof of concept for a long-term implantable risperidone delivery system in mice.

show abstract

Clinical review of a long-acting, injectable formulation of risperidone

Cited by 71 publications

References 15 publications

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders

Rapid Onset of Pedal Edema Associated with Risperidone in Two Male Patients: Simultaneous Clinical Cases

In vitro and in vivo demonstration of risperidone implants in mice

Contact Info

Product

Resources

About